Entheon Biomedical Corp.
ENBI
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.72% | -34.68% | -4.81% | 94.98% | 93.86% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -13.64% | -- | -- | -100.10% | -99.95% |
| Change in Net Operating Assets | -84.25% | 292.86% | 34.89% | -99.08% | 79.58% |
| Cash from Operations | -6.95% | -35.90% | 2.32% | 25.52% | -202.20% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -98.30% | -95.37% |
| Cash from Investing | -- | -- | -- | -98.30% | -95.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 238.98% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 222.92% | -- | -- | -- | 135.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -202.20% |
| Net Change in Cash | 149.34% | 205.35% | 38.69% | -215.29% | -1,535.00% |